Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 7/20 | 0.49 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102599 | 0.98 | CACNA1B (0.51) | CACNA1BCACNA1HKDM1AFPR2SIGMAR1 | |
| SCHEMBL9419635 | 0.97 | CACNA1B (0.50) | CACNA1BCACNA1HKDM1AFPR2SIGMAR1 | |
| SCHEMBL6102976 | 0.88 | PIM1 (0.59) | FPR2SIGMAR1CHRM2HTR1AADRA2A | |
| SCHEMBL29354742 | 0.86 | PIM1 (0.60) | CACNA1BCACNA1HSIGMAR1CHRM2HTR1A | |
| SCHEMBL6104044 | 0.86 | PIM1 (0.60) | CACNA1BCACNA1HSIGMAR1CHRM2HTR1A | |
| SCHEMBL9085509 | 0.86 | CACNA1B (0.50) | CACNA1BCACNA1HHRH3P2RX4 | |
| SCHEMBL13305145 | 0.86 | KDM1A (0.64) | CACNA1BKDM1AFPR2SIGMAR1CHRM2 | |
| SCHEMBL9419629 | 0.86 | KDM1A (0.67) | CACNA1BKDM1ASIGMAR1CHRM2HTR1A | |
| SCHEMBL13305231 | 0.85 | FPR2 (0.65) | FPR2SIGMAR1CHRM2HTR1AADRA2A | |
| SCHEMBL29577279 | 0.83 | FPR2 (0.64) | FPR2SIGMAR1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | claimed |
| US-9012217-B2 | Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012217-B2 | Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-04-21 | — | — | US | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | RCOR3, BRD3, BRPF3 | CACNA1B 1119/4885CACNA1H 2362/4885KDM1A 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.